These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16870302)

  • 21. Restricted randomization of ZAMSTAR: a 2 x 2 factorial cluster randomized trial.
    Sismanidis C; Moulton LH; Ayles H; Fielding K; Schaap A; Beyers N; Bond G; Godfrey-Faussett P; Hayes R
    Clin Trials; 2008; 5(4):316-27. PubMed ID: 18697846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomization procedures in orthopaedic trials.
    Randelli P; Arrigoni P; Lubowitz JH; Cabitza P; Denti M
    Arthroscopy; 2008 Jul; 24(7):834-8. PubMed ID: 18589273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal multivariate matching before randomization.
    Greevy R; Lu B; Silber JH; Rosenbaum P
    Biostatistics; 2004 Apr; 5(2):263-75. PubMed ID: 15054030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Issues for stratified randomization based on a factor derived from a continuous baseline variable.
    Qu Y
    Pharm Stat; 2011; 10(3):232-5. PubMed ID: 20922820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporating cost in power analysis for three-level cluster-randomized designs.
    Konstantopoulos S
    Eval Rev; 2009 Aug; 33(4):335-57. PubMed ID: 19509118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Starting from scratch: program development and lessons learned from HIV vaccine trial counseling in Thailand.
    Thapinta D; Jenkins RA
    Contemp Clin Trials; 2007 Jul; 28(4):409-22. PubMed ID: 17196444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New algorithm for treatment allocation reduced selection bias and loss of power in small trials.
    Hofmeijer J; Anema PC; van der Tweel I
    J Clin Epidemiol; 2008 Feb; 61(2):119-24. PubMed ID: 18177784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomization for clinical research: an easy-to-use spreadsheet method.
    Padhye NS; Cron SG; Gusick GM; Hamlin SK; Hanneman SK
    Res Nurs Health; 2009 Oct; 32(5):561-6. PubMed ID: 19606450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eliminating bias in randomized controlled trials: importance of allocation concealment and masking.
    Viera AJ; Bangdiwala SI
    Fam Med; 2007 Feb; 39(2):132-7. PubMed ID: 17273956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Various randomized designs can be used to evaluate medical tests.
    Lijmer JG; Bossuyt PM
    J Clin Epidemiol; 2009 Apr; 62(4):364-73. PubMed ID: 18945590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Control of selection bias in parallel-group controlled clinical trials in dogs and cats: 97 trials (2000-2005).
    Brown DC
    J Am Vet Med Assoc; 2006 Sep; 229(6):990-3. PubMed ID: 16978121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled trial to investigate impact of site-based safer sex programmes in Kingston, Jamaica: trial design, methods and baseline findings.
    Weir SS; Figueroa JP; Byfield L; Hall A; Cummings S; Suchindran C
    Trop Med Int Health; 2008 Jun; 13(6):801-13. PubMed ID: 18482079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of chance baseline differences in repeated measurement designs.
    Overall JE; Doyle SR
    J Biopharm Stat; 1994 Jul; 4(2):199-216. PubMed ID: 7951275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A SAS/IML program for implementing the modified Brown-Forsythe procedure in repeated measures designs.
    Vallejo G; Moris J; Conejo NM
    Comput Methods Programs Biomed; 2006 Sep; 83(3):169-77. PubMed ID: 16934362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size determination for hierarchical longitudinal designs with differential attrition rates.
    Roy A; Bhaumik DK; Aryal S; Gibbons RD
    Biometrics; 2007 Sep; 63(3):699-707. PubMed ID: 17825003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constrained randomization in a therapeutic efficacy trial.
    Tamura RN; Mills BJ; Lovelace JK
    Biometrics; 1993 Mar; 49(1):249-58. PubMed ID: 8513107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomization. Part 1: sequence generation.
    Pandis N
    Am J Orthod Dentofacial Orthop; 2011 Nov; 140(5):747-8. PubMed ID: 22051497
    [No Abstract]   [Full Text] [Related]  

  • 40. Randomized trials for the real world: making as few and as reasonable assumptions as possible.
    Baker SG; Kramer BS
    Stat Methods Med Res; 2008 Jun; 17(3):243-52. PubMed ID: 17925312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.